Table 1.
Baseline characteristics
| Characteristic | Lenalidomide maintenance, n = 213 | No maintenance, n = 165 |
|---|---|---|
| Age | ||
| Median (range), y | 60 (24-78) | 60 (27-75) |
| <65 y, n (%) | 149 (70.0) | 113 (68.5) |
| 65 to <75 y, n (%) | 62 (29.1) | 51 (30.9) |
| Male sex, n (%) | 134 (62.9) | 93 (56.4) |
| Race, n (%) | ||
| White | 182 (85.4) | 139 (84.2) |
| African American | 24 (11.3) | 18 (10.9) |
| ECOG PS, n (%) | ||
| 0 or 1 | 136 (63.8) | 113 (68.4) |
| 2 or 3 | 13 (6.1) | 7 (4.2) |
| Not specified | 64 (30.0) | 45 (27.3) |
| ISS stage, n (%) | ||
| I | 57 (26.8) | 50 (30.3) |
| II | 64 (30.0) | 36 (21.8) |
| III | 49 (23.0) | 44 (26.7) |
| Not specified | 43 (20.2) | 35 (21.2) |
| Serum creatinine, n (%), mg/dL | ||
| >2.0 | 26 (12.2) | 31 (18.8) |
| ≤2.0 | 187 (87.8) | 134 (81.2) |
| IMWG risk,* n (%) | ||
| Standard | 104 (48.8) | 85 (51.5) |
| High | 44 (20.7) | 27 (16.4) |
| Not specified | 65 (30.5) | 53 (32.1) |
ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescent in situ hybridization; IMWG, International Myeloma Working Group; ISS, International Staging System.
*
High-risk: ISS II/III and t(4;14) or del(17p); standard-risk: ISS I/II, absence of t(4;14) or del(17p) and/or other cytogenetic/FISH abnormalities, and ISS III without cytogenetic abnormalities.17